Results 71 to 80 of about 35,531 (245)

Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds [PDF]

, 2018
PURPOSE: 18F-Florbetapir has been reported to show cardiac uptake in patients with systemic light-chain amyloidosis (AL). This study systematically assessed uptake of 18F-florbetapir in patients with proven systemic amyloidosis at sites outside the heart.
Burniston, M, Hawkins, PN, Manwani, R, McCool, D, Page, J, Ross, JC, Skillen, A, Wagner, T, Wechalekar, AD   +8 more
core   +1 more source

Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR‐CM

ESC Heart Failure, EarlyView.
Abstract Aims Patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) often experience delayed diagnosis, which may detrimentally impact clinical outcomes. This study aimed to assess the frequency of use of planar scintigraphy with and without single‐photon emission computed tomography (SPECT) in patients with hypertrophic cardiomyopathy (HCM ...
Pablo Garcia‐Pavia, Francisco Javier Haro del Moral, Francesco Cappelli, Nicolas Piriou, Roberto Barriales‐Villa, Carmen Munteanu, Catherine Bahus, Denis Keohane, Pablo Mallaina, Emmanuel Itti, Thibaud Damy, Perry Elliott   +11 more
wiley   +1 more source

Subcutaneous scalp nodule as the presenting symptom of systemic light-chain amyloidosis

Dermatology Practical & Conceptual, 2018
We present a case of subcutaneous nodular amyloidosis mimicking a pilar cyst. Further evaluation led to the diagnosis of malignant systemic light-chain amyloidosis. The epidemiology and histopathological features of light-chain amyloidosis with cutaneous
Joseph Tadros, Stacey Goodman, Eric R. Tkaczyk   +2 more
doaj  

The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis

European Journal of Heart Failure, EarlyView.
Proposed algorithm to screen for transthyretin cardiac amyloidosis (ATTR‐CA). AL‐CA, immunoglobulin light‐chain cardiac amyloidosis; AMYLI, AMYLoidosis Index; AUC, area under the curve; IWT, increased wall thickness; LVEF, left ventricular ejection fraction; PYP, pyrophosphate.
Giovanni Battista Bonfioli, Daniela Tomasoni, Giuseppe Vergaro, Vincenzo Castiglione, Marianna Adamo, Iacopo Fabiani, Victor Loghin, Carlo Mario Lombardi, Alessio Nicolai, Marco Metra, Michele Emdin, Alberto Aimo   +11 more
wiley   +1 more source

Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis [PDF]

, 2016
Search strategy.
Lei Zhao, Quan Fang, Zhuang Tian
core   +2 more sources

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

Biomarker Research, 2023
Light chain amyloidosis (AL) is a rare disease caused by the generalized deposition of misfolded free light chains. Patients with immunoglobulin M gammopathy (IgM) and indolent B-cell lymphoma such as marginal zone lymphoma (MZL) may in some instances ...
Felix Korell, Stefan Schönland, Anita Schmitt, Madelaine Jansen, Kiavasch Farid, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Ute Hegenbart   +8 more
doaj   +1 more source

Classic features of primary systemic amyloidosis (AL amyloidosis) leading to diagnosis of plasma cell myeloma [PDF]

, 2019
The diagnosis of primary systemic amyloidosis, also known as AL (amyloid light-chain) amyloidosis, is often delayed owing to its nonspecific manifestations as well as its rarity.
Behrens, Emily, Tan, Kendra W, Tarbox, Michelle B, Zhu, Brian   +3 more
core  

Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. [PDF]

, 2015
Cardiac involvement determines outcome in patients with systemic amyloidosis. There is major unmet need for quantification of cardiac amyloid burden, which is currently only met in part through semi-quantitative bone scintigraphy or Cardiovascular ...
Bandula, S, Fontana, M, Gilbertson, JA, Gillmore, JD, Hawkins, PN, Herrey, AS, Moon, JC, Punwani, S, Taylor, SA, Treibel, TA, White, SK   +10 more
core   +1 more source

Long‐term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage

European Journal of Heart Failure, EarlyView.
Long‐term efficacy of tafamidis in patients with ATTR‐CM in ATTR‐ACT and its LTE by NAC stage at ATTR‐ACT baseline. ATTR‐ACT, Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; ATTR‐CM, transthyretin amyloid cardiomyopathy; NAC, National Amyloidosis Centre.
Thibaud Damy, Rong Wang, Mathew S. Maurer, Julian D. Gillmore, Marianna Fontana   +4 more
wiley   +1 more source

Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio‐Oncology

European Journal of Heart Failure, EarlyView.
Specific characteristics of HFpEF universal definition in cancer patients. Abstract Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized in cancer patients and survivors, yet it remains underdiagnosed and its epidemiology largely unknown.
Kalliopi Keramida, Teresa Lopez‐Fernandez, Markus S. Anker, Mark C. Petrie, Pietro Ameri, Lisa J. Anderson, Jutta Bergler‐Klein, Anita Deswal, Dimitrios Farmakis, Borja Ibañez, Carolyn S.P. Lam, Ninian N. Lang, Alexander R. Lyon, Mariana Mirabel, Brenda Moura, Walter J. Paulus, Amina Rakisheva, Gianluigi Savarese, Michele Senni, Carlo Gabriele Tocchetti, Marco Metra, Gerasimos Filippatos   +21 more
wiley   +1 more source